Candel Therapeutics Inc (CADL) - Net Assets
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has net assets worth $138.03 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($201.92 Million) and total liabilities ($63.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Candel Therapeutics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $138.03 Million |
| % of Total Assets | 68.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | -19.05% |
| 10-Year Change | N/A |
| Growth Volatility | 200.49 |
Candel Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Candel Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Candel Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Candel Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see CADL company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $51.92 Million | -21.72% |
| 2024-12-31 | $66.33 Million | +420.42% |
| 2023-12-31 | $12.74 Million | -73.29% |
| 2022-12-31 | $47.71 Million | -25.61% |
| 2021-12-31 | $64.14 Million | +372.21% |
| 2020-12-31 | $-23.56 Million | -193.13% |
| 2019-12-31 | $-8.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Candel Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20389600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $550.00K | 1.06% |
| Other Components | $281.76 Million | 542.66% |
| Total Equity | $51.92 Million | 100.00% |
Candel Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Candel Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
$598.00 Million |
|
Velesto Energy Bhd
KLSE:5243
|
$598.17 Million |
|
Haier Smart Home Co Ltd
F:690D
|
$598.26 Million |
|
Naphtha
TA:NFTA
|
$598.40 Million |
|
Sunplus Technology Co Ltd
TW:2401
|
$597.88 Million |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
$597.84 Million |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
$597.45 Million |
|
EPC Groupe
PA:EXPL
|
$597.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Candel Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 66,327,000 to 51,922,000, a change of -14,405,000 (-21.7%).
- Net loss of 38,182,000 reduced equity.
- New share issuances of 19,369,000 increased equity.
- Other factors increased equity by 4,408,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.18 Million | -73.54% |
| Share Issuances | $19.37 Million | +37.3% |
| Other Changes | $4.41 Million | +8.49% |
| Total Change | $- | -21.72% |
Book Value vs Market Value Analysis
This analysis compares Candel Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.43 | $8.31 | x |
| 2020-12-31 | $-1.26 | $8.31 | x |
| 2021-12-31 | $2.24 | $8.31 | x |
| 2022-12-31 | $1.66 | $8.31 | x |
| 2023-12-31 | $0.44 | $8.31 | x |
| 2024-12-31 | $2.09 | $8.31 | x |
| 2025-12-31 | $0.98 | $8.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Candel Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.41x
- Recent ROE (-73.54%) is above the historical average (-78.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -6592.00% | 0.00x | 0.00x | $-7.44 Million |
| 2020 | 0.00% | -14144.00% | 0.00x | 0.00x | $-15.32 Million |
| 2021 | -56.32% | -28899.20% | 0.00x | 1.39x | $-42.54 Million |
| 2022 | -39.39% | -15035.20% | 0.00x | 1.65x | $-23.57 Million |
| 2023 | -297.68% | -122383.87% | 0.00x | 3.23x | $-39.21 Million |
| 2024 | -83.19% | 0.00% | 0.00x | 1.61x | $-61.81 Million |
| 2025 | -73.54% | 0.00% | 0.00x | 2.41x | $-43.37 Million |
Industry Comparison
This section compares Candel Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Candel Therapeutics Inc (CADL) | $138.03 Million | 0.00% | 0.46x | $597.89 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more